The FDA has granted Priority Review to AstraZeneca’s Calquence (acalabrutinib) for the treatment of previously untreated mantle cell lymphoma (MCL). This decision follows promising results from the ECHO Phase III trial, which demonstrated that Calquence, in combination with bendamustine and rituximab, significantly reduced the risk of disease progression or death compared to standard-of-care chemotherapy.